Lumosa Therapeutics Co., Ltd. (6535.TWO)
- Previous Close
159.00 - Open
163.50 - Bid 160.00 x --
- Ask 162.00 x --
- Day's Range
159.00 - 166.00 - 52 Week Range
129.00 - 400.00 - Volume
200,380 - Avg. Volume
259,824 - Market Cap (intraday)
27.264B - Beta (5Y Monthly) 0.09
- PE Ratio (TTM)
-- - EPS (TTM)
-2.55 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
230.00
Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops therapies and solutions for neurological and oncological diseases in Taiwan, Asia, the Americas, and Europe. The company offers Naldebain (LT 1001), an analgesic injection for severe pain relief after surgery. It is developing LT3001, which is in Phase II clinical trial for the treatment of acute ischemic stroke; LT5001 that has completed Phase I clinical trial for uremic pruritus; LT6001 that is in pre-clinical trials for neurological disorders; and LT2003, which is in pre-clinical stage for the treatment of oncology. In addition, the company engages in the investment, consulting, service, and transfer of techniques activities. Lumosa Therapeutics Co., Ltd. was incorporated in 2000 and is headquartered in Taipei, Taiwan.
www.lumosa.com.twRecent News: 6535.TWO
View MorePerformance Overview: 6535.TWO
Trailing total returns as of 5/13/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 6535.TWO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 6535.TWO
View MoreValuation Measures
Market Cap
26.84B
Enterprise Value
25.58B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
600.02
Price/Book (mrq)
14.80
Enterprise Value/Revenue
586.95
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-13.38%
Return on Equity (ttm)
-26.98%
Revenue (ttm)
43.59M
Net Income Avi to Common (ttm)
-413.35M
Diluted EPS (ttm)
-2.55
Balance Sheet and Cash Flow
Total Cash (mrq)
1.27B
Total Debt/Equity (mrq)
0.66%
Levered Free Cash Flow (ttm)
-169.84M